NRP2 and Alzheimer disease: Moreover, the immunoreactivity against Nrp-2, one of the molecular targets for miR-188-5p, was markedly increased (318.02 ± 10.86%, p < 0.001; Fig. 1b,c) in the hippocampi of AD patients compared with age-matched control subjects.